Filgotinib | CAS No. 1206161-97-8

Filgotinib

Basic Information

View in Editor

CAS Number

1206161-97-8

Molecular Formula

C21H23N5O3S

Molecular Weight

425.51 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Dyes and Pigments Organic Dyes

Fine Chemicals Surfactants Anionic Surfactants

Laboratory Chemicals Research Chemicals Biochemical Reagents

Basic Physical Properties

Solubility

Insuluble (7.2E-3 g/L) (25 ºC),

SMILES

View in Editor

C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5

InChI

InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)

InChIKey

RIJLVEAXPNLDTC-UHFFFAOYSA-N

LogP

1.9751999999999998

Topological Polar Surface Area

96.67 Å²

Hydrogen Bond Donor/Acceptor

1 / 8

Complexity

715

Safety Information

View Safety Information

Hazard Statement

H302 Harmful if swallowed
Acute toxicity, oral

H315 Causes skin irritation
Skin corrosion/irritation

H319 Causes serious eye irritation
Serious eye damage/eye irritation

H335 May cause respiratory irritation
Specific target organ toxicity, single exposure; Respiratory tract irritation

Synonyms & References

English

Filgotinib
Filgotinib (GLPG0634)
GLPG0634
GLPG-0634 (Filgotinib)
GPLG0634
GPLG-0634
N-(5-(4-((1,1-Dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
cyclopropanecarboxylic acid {5-[ 4-(1,1-dioxo-thiomorpholin-4-ylmethyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}-amide
cyclopropanecarboxylic acid {5-[4-((1,1-dioxo-1-thimorpholin-4-yl)methyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}-amide
GLPG-0634
N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
SYN1158
UNII-3XVL385Q0M
GLPG0634 （Filgotinib）
3XVL385Q0M
AK171369
Filgotinib [USAN:INN]
GLPG 0634
N-(5-{4-[
Filgotinib(GLPG0634)
G146034
N-(5-(4-((1,1-dioxido
N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
FILGOTINIB [USAN]
AMY3802
BDBM103727
AKOS025291103
N-(5-{4-[(1,1-dioxo-1lambda6-thiomorpholin-4-yl)methyl]phenyl}-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
Filgotinib (USAN/INN)
A892158

MDL Number

MFCD20527867

FAQ

What regulatory guidelines apply to filgotinib (CAS: 1206161-97-8)?

Filgotinib (CAS: 1206161-97-8) is subject to various regulatory guidelines, including the Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) regulations in the European Union, which require manufacturers and importers to register substances above a threshold of 1 tonne per year. In the United States, it complies with FDA and EPA regulations, which include proper labeling, storage, and handling to ensure public safety and environmental protection. Additionally, it must adhere to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) for research and development purposes.

Are there alternatives to filgotinib (CAS: 1206161-97-8) in synthesis?

Filgotinib (CAS: 1206161-97-8) can have several alternatives in synthesis, such as using similar JAK inhibitors like tofacitinib or baricitinib. Isomers and analogs, like filgotinib itself, can also serve as alternatives depending on the specific requirements of the synthesis. Common alternative reagents include different transition metals or ligands in catalytic systems, or different protecting groups in organic transformations.

What is the market or research trend for filgotinib (CAS: 1206161-97-8)?

The market for filgotinib (CAS: 1206161-97-8) is showing steady growth, driven by its successful clinical trials and regulatory approvals for treating rheumatoid arthritis and ulcerative colitis. Research trends include exploring its efficacy in other autoimmune diseases and understanding its mechanisms of action. The trend also includes developing biosimilars and studying its potential in combination therapies. Market demand is expected to increase with ongoing clinical trials and positive responses from patients.

How should waste containing filgotinib (CAS: 1206161-97-8) be handled?

Waste containing filgotinib (CAS: 1206161-97-8) should be collected and disposed of according to local and national regulations. Waste liquids should be neutralized and collected in appropriate containers for incineration or professional waste disposal. Environmental precautions include ensuring that no hazardous substances are released into the environment. Proper handling, labeling, and storage are essential to prevent spills or leaks. Employing trained personnel and following safety protocols is crucial to manage waste safely and effectively.